
Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence to learn the language of life and transform how we treat disease. The company seeks to rethink the drug discovery and development process from end-to-end by bringing together leading talent across three core areas: machine learning research to better understand biology, expansive data generation to power new models, and robust therapeutic product development to treat disease. Xaira is headquartered in the San Francisco Bay Area.

Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence to learn the language of life and transform how we treat disease. The company seeks to rethink the drug discovery and development process from end-to-end by bringing together leading talent across three core areas: machine learning research to better understand biology, expansive data generation to power new models, and robust therapeutic product development to treat disease. Xaira is headquartered in the San Francisco Bay Area.
Sector: AI-driven drug discovery / biotechnology
Headquarters: South San Francisco, CA
Launch / Major financing: Launched April 2024 with ~ $1B initial financing
Core focus: Machine learning research, large-scale biological data generation, therapeutic development
Employee count: 191
Accelerating and improving the drug discovery and development process using AI and biological data.
Biotechnology Research
$1 billion (reported)
Company launched from stealth with reported committed capital of approximately $1B.
“Backed and incubated by prominent life-science investors including ARCH Venture Partners and Foresite Labs; syndicate reported to include Sequoia, Lux Capital, NEA, F-Prime, Lightspeed, Menlo Ventures and Two Sigma Ventures.”
| Company |
|---|